Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,992 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T, Ebiike H, Taka N, Aoki Y, Ishii N. Nakanishi Y, et al. Among authors: sakata k. Mol Cancer Ther. 2014 Nov;13(11):2547-58. doi: 10.1158/1535-7163.MCT-14-0248. Epub 2014 Aug 28. Mol Cancer Ther. 2014. PMID: 25169980
Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y. Ono N, et al. Among authors: sakata k. Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13. Cancer Sci. 2012. PMID: 22050138 Free article.
Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
Tanaka H, Sase H, Tsukaguchi T, Hasegawa M, Tanimura H, Yoshida M, Sakata K, Fujii T, Tachibana Y, Takanashi K, Higashida A, Hasegawa K, Ono Y, Oikawa N, Mio T. Tanaka H, et al. Among authors: sakata k. Mol Cancer Ther. 2018 Dec;17(12):2519-2529. doi: 10.1158/1535-7163.MCT-17-1180. Epub 2018 Sep 21. Mol Cancer Ther. 2018. PMID: 30242093
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Sano Y, et al. Among authors: sakata k. Mol Cancer Ther. 2015 Feb;14(2):533-41. doi: 10.1158/1535-7163.MCT-14-0456. Epub 2014 Dec 18. Mol Cancer Ther. 2015. PMID: 25522765
MITF suppression by CH5552074 inhibits cell growth in melanoma cells.
Aida S, Sonobe Y, Yuhki M, Sakata K, Fujii T, Sakamoto H, Mizuno T. Aida S, et al. Among authors: sakata k. Cancer Chemother Pharmacol. 2017 Jun;79(6):1187-1193. doi: 10.1007/s00280-017-3317-6. Epub 2017 Apr 26. Cancer Chemother Pharmacol. 2017. PMID: 28447210
YES1 Is a Targetable Oncogene in Cancers Harboring YES1 Gene Amplification.
Hamanaka N, Nakanishi Y, Mizuno T, Horiguchi-Takei K, Akiyama N, Tanimura H, Hasegawa M, Satoh Y, Tachibana Y, Fujii T, Sakata K, Ogasawara K, Ebiike H, Koyano H, Sato H, Ishii N, Mio T. Hamanaka N, et al. Among authors: sakata k. Cancer Res. 2019 Nov 15;79(22):5734-5745. doi: 10.1158/0008-5472.CAN-18-3376. Epub 2019 Aug 7. Cancer Res. 2019. PMID: 31391186
1,992 results